AMCP 2023 Conference to Feature New Outcomes Research from Analysis Group
March 2, 2023
Analysis Group’s HEOR, Epidemiology & Market Access practice will present 17 posters, including gold, silver, and bronze awardees and several encore presentations, at the Academy of Managed Care Pharmacy’s (AMCP’s) 2023 Meeting, which will be held March 21 to 24 in San Antonio, TX.
Gold Ribbon
- “Improvement in Health-Related Quality of Life and Estimated Economic Benefits in Patients with Recurrent Clostridioides Difficile Infection with No Further Recurrences: Pooled Results from the RBX2660 Phase 2 Randomized, Placebo-Controlled Trial,” coauthored by an Analysis Group team – including Vice Presidents Min Yang and Viviana García-Horton and Manager Mirko Fillbrunn – in collaboration with researchers from the Gastroenterology Center of Connecticut, Washington University in St. Louis, the University of Houston, and Ferring.
Silver Ribbon
- “Risk of Falls and Healthcare Resource Utilization Burden of Geographic Atrophy and Visual Impairment/Blindness in US Elderly Patients,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President Wendy Cheng, Manager Guillaume Germain, and Associates Malena Mahendran and Jacob Klimek – in collaboration with a team from Apellis.
Bronze Ribbon
- Real-world clinical and economic value of switching to a non-TNFi advanced therapy compared with TNFi cycling in psoriatic arthritis,” coauthored by an Analysis Group team – including Vice President Yan Song, Manager Yan Wang, and Associate Sophie Gao – in collaboration with researchers from AbbVie and the Hospital for Special Surgery.
Additional poster presentations include:
- “The budget impact to US health plans from adding darolutamide to docetaxel for treatment of metastatic hormone-sensitive prostate cancer,” coauthored by an Analysis Group team – including Managing Principal Mihran Yenikomshian, Manager Michael Carson, and Senior Analyst Josie Maynard – in collaboration with a team from Bayer.
- “A Comparison of Persistence, Adherence, and Healthcare Costs Among Patients with Chronic Migraine Treated with OnabotulinumtoxinA or CGRP Monoclonal Antibodies,” coauthored by an Analysis Group team – including Vice President François Laliberté, Manager Enrico Zanardo, Manager Sean MacKnight, and Senior Research Professional Ana Urosevic – in collaboration with researchers from AbbVie.
- “Corticosteroid use and adherence in patients treated with Acthar Gel for advanced sarcoidosis,” coauthored by an Analysis Group team – including Managing Principal Brad Rice, Senior Analysts Nathaniel Downes and Ella Hagopian, and Analyst Izzy Ma – in collaboration with a team from Mallinckrodt.
- “Cost-Effectiveness Analysis of RBX2660 for Preventing/Reducing Recurrent Clostridioides difficile Infections in the US,” coauthored by an Analysis Group team – including Vice President Min Yang, Managers Erin Cook and Wei Song, Senior Analyst Danni Yang, and Analyst Angela Zhao – in collaboration with researchers from Ferring, Outpatient Integrated Strategies, and the Albany College of Pharmacy and Health Sciences.
- “Economic Burden of Major Depressive Disorder with Insomnia Symptoms (MDDIS) among Commercially and Medicaid Insured Individuals in the United States,” coauthored by an Analysis Group team – including Vice President Dominic Pilon, Manager Masha Zhdanava, and Associates Paul Boonmak and Aditi Shah – in collaboration with researchers from the University of Texas and Janssen Scientific Affairs.
- “Payer Budget Impact Analysis of RBX2660 for Preventing/Reducing Recurrent Clostridioides difficile Infections in the US,” coauthored by an Analysis Group team – including Vice President Min Yang, Managers Erin Cook and Wei Song, Senior Analyst Danni Yang, and Analyst Angela Zhao – in collaboration with researchers from Ferring, Outpatient Integrated Strategies, and the Albany College of Pharmacy and Health Sciences.
- “A Real-World Assessment of Healthcare Resource Utilization Among Patients With APDS in the United States,” coauthored by an Analysis Group team – including Vice President François Laliberté, Manager Guillaume Germain, Associate Malena Mahendran, and Senior Research Professional Ana Urosevic – in collaboration with researchers from Pharming.
- “Response and all-cause medical service costs in patients with ankylosing spondylitis (AS) who cycled through TNFi therapies,” coauthored by an Analysis Group team – including Vice President Yan Song, Manager Yan Wang, and Associate Sophie Gao – in collaboration with researchers from AbbVie and Oregon Health & Science University.
- “Treatment patterns and outcomes in patients with spinal muscular atrophy (SMA): real-world findings of a retrospective US claims database analysis,” coauthored by an Analysis Group team – including Vice President Min Yang, Managers Mihaela Georgieva and Wei Song, Associate Anya Jiang, and Analyst Angela Zhao – in collaboration with a team from Novartis.
Encore presentations:
- “Clinical management of Rett syndrome in the real world: a physician survey,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Wendy Cheng, Manager Ambika Satija, and Senior Analysts Neema Lema and Andra Boca – in collaboration with researchers from Vanderbilt University, Acadia Pharmaceuticals, and HCA Healthcare.
- “Real-world effectiveness of dupilumab and other biologics on asthma exacerbations and steroid prescriptions: US ADVANTAGE study,” coauthored by Vice President Lynn Huynh in collaboration with researchers from The University of Arizona College of Medicine, the Medical College of Georgia at Augusta University, Sanofi, Regeneron, and AESARA.
- “Real-world prostate-specific antigen response and metastasis-free survival among patients with non-metastatic castration-resistant prostate cancer initiated on apalutamide,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Dominic Pilon, Manager Carmine Rossi, Senior Research Professional Frederic Kinkead, and Research Professional Bronwyn Moore – in collaboration with researchers from Janssen Scientific Affairs and Chesapeake Urology.
- “Real-world time-to-castration resistance among patients with metastatic castration-sensitive prostate cancer initiating apalutamide, enzalutamide, or abiraterone acetate from an oncology database,” coauthored by an Analysis Group team – including Managing Principal Patrick Lefebvre, Vice President Dominic Pilon, Manager Carmine Rossi, and Senior Research Professional Frederic Kinkead – in collaboration with researchers from Janssen Scientific Affairs, Chesapeake Urology, and the Huntsman Cancer Institute at the University of Utah.
- “Treatment patterns for patients initiating dupilumab for asthma in the US: Findings from the US ADVANTAGE study,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh and Senior Analysts Tracy Guo and Mingchen Ye – in collaboration with researchers from The University of Arizona College of Medicine, the Medical College of Georgia at Augusta University, Sanofi, Regeneron, and AESARA.